Trials / Active Not Recruiting
Active Not RecruitingNCT06938854
Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries
Prospective, Multi-center, Single-arm Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Shockwave Medical, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Disrupt PAD Japan is a prospective, multi-center, single-arm study of SWM-831 to treat moderate and severely calcified femoropopliteal arteries, prior to DCB or stenting.
Detailed description
Up to 60 subjects at up to 10 sites in Japan will be enrolled in the femoropopliteal clinical study with moderate and severely calcified femoropopliteal artery disease presenting with Rutherford Category 2 - 5 of the target limb. Two additional cohorts \[Iliac and BTK (Below-the-Knee)\] will enroll a minimum of 10 and a maximum of 15 subjects each with moderate and severely calcified iliac disease with a Rutherford Category (RC) 2 - 5 and a minimum of 10 and a maximum of 15 subjects with moderate and severely calcified BTK lesions with a Rutherford Category (RC) 2 - 5 will be enrolled and followed through 12 months. The estimated study duration for these cohorts is approximately 24 months. Study subjects will be followed through discharge, 30 days, 6, and 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Peripheral Intravascular Lithotripsy (IVL) | For the Disrupt PAD Japan study, the Shockwave Medical Peripheral IVL System (SWM-831) is intended for lithotripsy enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the femoropopliteal arteries. |
Timeline
- Start date
- 2025-03-10
- Primary completion
- 2027-01-31
- Completion
- 2028-03-01
- First posted
- 2025-04-22
- Last updated
- 2025-12-11
Locations
10 sites across 1 country: Japan
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06938854. Inclusion in this directory is not an endorsement.